Atara Biotherapeutics, Inc. Overview
Pro stress-test →Atara Biotherapeutics develops off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. The company is the first in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. The company is currently in strategic transition following a recent FDA rejection of its lead therapy.
Strategic Profile
Pro stress-test →Atara's advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and targets EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts for hematological malignancies and B-cell driven autoimmune diseases. The company has resumed evaluating strategic options, including potential acquisition, merger, or other business combinations.
Competitive Landscape
Pro stress-test →There are no FDA approved therapies in the EBV+ PTLD treatment setting. Atara faces competition from other cell therapy developers in oncology and autoimmune diseases, but its allogeneic off-the-shelf approach represents a differentiated model compared to patient-derived therapies. The company's recent pivot to partnership and strategic alternatives reflects a consolidated competitive position.
Industry Context
Atara Biotherapeutics, Inc. operates in Biotechnology - Cell Immunotherapy.
Key facts
Headquarters: Thousand Oaks, California · Revenue: N/A · Market cap: $35.84M